Ask AI
ProCE Banner Activity

CE / CME

France—Regional Perspectives on the Management of Patients With R/R CLL/SLL

Slideset

Download this slideset to explore the treatment algorithm for relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) in France, including current standards of care, emerging treatment strategies, and safety considerations.

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Released: April 14, 2026

Expiration: October 13, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with Lymphoma Coalition.

ProCE Banner

Supporters

Supported by educational grants from Lilly and Merck Sharp & Dohme LLC.

Lilly

Merck Sharp & Dohme, LLC

Partners

Lymphoma Coalition

ProCE Banner

Target Audience

This activity has been designed to meet the educational needs of global hematologists, oncologists, nurse practitioners, physician associates, oncology nurses, pharmacists, and other healthcare professionals caring for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Program Learning Goal

This activity aims to improve learners’ knowledge, competence, and performance in providing patient-centric, data-driven, culturally sensitive care for individuals with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma based on the latest clinical evidence and local expert recommendations.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan individualized treatment sequences to optimize clinical outcomes for patients with relapsed/refractory CLL/SLL, considering available evidence, local expert recommendations, regional guidelines, and disease/patient factors

  • Appraise emerging clinical evidence for novel BTK-targeted therapies and the clinical implications for management of relapsed/refractory CLL/SLL

  • Assess resistance mutations in patients with relapsed/refractory CLL/SLL who progressed on or following covalent BTK inhibitor therapy

  • Implement multidisciplinary team processes to mitigate the risk of treatment- and disease-related complications in patients with relapsed/refractory CLL/SLL

  • Apply shared decision-making strategies to support patient quality of life and engagement in care for relapsed/refractory CLL/SLL

Disclosure

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Matthew S. Davids, MD, MMSc: consultant: AbbVie, Ascentage, AstraZeneca, BeiGene/BeOne, Bristol Myers Squibb, Galapagos, Genentech, Genmab, Janssen, Lilly, MEI Pharma, Merck, Nuvalent, Schrödinger; researcher: Ascentage, AstraZeneca, MEI Pharma.

Stéphane Lepretre, MD, has no relevant financial relationships to disclose.

Javier Loscertales, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeOne, Johnson & Johnson, Lilly.

Stephen Stilgenbauer, MD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Galapagos, Gilead, GSK, Hoffmann-La Roche, Johnson & Johnson; researcher: AbbVie, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Galapagos, Gilead, GSK, Hoffmann-La Roche, Johnson & Johnson.

Alessandra Tedeschi, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeOne, Johnson & Johnson, Lilly.

The planners and content peer reviewers from Decera Clinical Education and Lymphoma Coalition do not have any relevant financial relationships to disclose, except Kristi K. Orbaugh, MSN, NP, AOCNP, as noted below:

Kristi K. Orbaugh, MSN, NP, AOCNP: speaker: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, DSI, Exelixis, Lilly, Pfizer, Stemline.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 14, 2026, through October 13, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC dba Decera Clinical Education and Lymphoma Coalition. Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.

Continuing Pharmacy Education

Clinical Care Options, LLC dba Decera Clinical Education designates this continuing education activity for 1 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-9999-26-276-H01-P

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education 

AAPA CME Accreditation - AAPA

Clinical Care Options, LLC dba Decera Clinical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until October 13, 2026. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.

CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit cmepassport.org to create your account.